Table 3.
SF-36 and SF-12 scores of FM groups and comparison groups in cross-sectional clinical studies
| SF-36 health survey scores (SD) | SF-36 summary scores | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference (country) Study groups | n* | Mean age (SD) | PF | RP | BP | GH | VT | SF | RE | MH | PCS | MCS |
| Pagano et al. (2004) (Brazil) (45) | ||||||||||||
| FM | 40 | 49.4 (6.0) | 33.0a (19.6) | 9.38a (22.4) | 30.2a (14.83) | 45.7a (21.7) | 33.1a (21.3) | 44.0a (26.5) | 30.8a (38.8) | 45.6a (22.1) | ||
| Controls | 40 | 49.5 (7.7) | 86.6 (16.5) | 90.0 (22.5) | 76.7 (20.8) | 81.5 (17.8) | 67.9 (20.4) | 82.9 (22.1) | 77.5 (37.3) | 75.7 (14.8) | ||
| Ulaş et al. (2006) (46)/Alanoğlu et al. (2004) (47) (Turkey) | ||||||||||||
| FM | 34 | 37 (10) | 41.0a (18.0) | 13.0a (17.0) | 27.0a (15.0) | 28.0a (11.0) | 26.0a (13.0) | 42.0a (21.0) | 18.0a (24.0) | 36.0a (14.0) | ||
| Controls | 22 | 37 (10) | 76.0 (20.0) | 93.0 (20.0) | 63.0 (18.0) | 59.0 (10.0) | 68.0 (15.0) | 82.0 (19.0) | 95.0 (12.0) | 66.0 (10.0) | ||
| Martinez et al. (2001) (Brazil) (48) | ||||||||||||
| FM | 32 | 36.8 | 14.8a | 39.4a | 26.5a | 43.3a | 38.6b | 45.1a | 32.3b | 44.3b | ||
| Controls | 28 | 40.5 | 82.1 | 84.6 | 68.9 | 73.3 | 59.6 | 78.0 | 78.5 | 67.4 | ||
| Raj et al. (2000) (Canada) (49) | ||||||||||||
| FM | 17 | 41.8 (6.5) | 44.1a (22.0) | 10.3a (25.1) | 32.9a (15.5) | 36.0a (15.6) | 25.3a (12.9) | 39.7a (18.9) | 51.0b (45.8) | 57.9a (12.7) | ||
| Controls | 14 | 35.1 (7.7) | 96.8 (7.9) | 91.1 (21.0) | 93.2 (9.1) | 71.4 (11.3) | 80.7 (7.0) | 95.5 (9.3) | 95.2 (12.1) | 89.7 (11.3) | ||
| Tüzün (2002) (Turkey) (34) | ||||||||||||
| FM | 33 | 41.6 (7.3) | 67.3a (18.6) | 39.1a (37.3) | 33.2ae (17.7) | 36.4ad (22.3) | 39.3ae (19.8) | 59.1b (28.2) | 44.4bf (43.8) | 54.9c (21.9) | ||
| MPS | 33 | 40.4 (9.6) | 75.2a (15.0) | 58.6b (39.8) | 45.6a (16.6) | 60.7 (23.0) | 59.2 (23.0) | 71.8 (22.6) | 67.6 (37.8) | 66.1 (20.7) | ||
| Controls | 33 | 39.0 (5.4) | 89.4 (16.4) | 83.3 (28.4) | 73.6 (22.3) | 72.1 (17.7) | 60.9 (22.6) | 77.7 (25.9) | 72.7 (36.8) | 66.3 (17.4) | ||
| DaCosta et al. (2000) (Canada) (16) | ||||||||||||
| FM | 46 | 46.13 (9.4) | 46.7d (26.9) | 16.3d (30.8) | 32.7d (22.3) | 39.1 (26.2) | 29.9d (19.09) | 53.5f (27.5) | 52.9f (41.3) | 59.2 (20.8) | 29.6d (9.0) | 43.12 (10.8) |
| SLE | 59 | 42.36 (11.3) | 65.3 (25.0) | 42.4 (43.1) | 52.8 (25.5) | 44.5 (20.1) | 44.1 (19.2) | 64.6 (27.5) | 70.1 (42.3) | 65.0 (19.2) | 37.6 (11.1) | 46.14 (11.5) |
| Neumann et al. (2000) (Israel) (18) | ||||||||||||
| FM | 90 | 48 (10) | 34b (22) | 18b (29) | 26b (17) | 38b (19) | 42b (20) | 45b (29) | 59b (48) | 51c (17) | ||
| Newly Dx FM | 37 | 58 (11) | 28b (23) | 14b (29) | 17b (16) | 20b (16) | 40b (21) | 22b (20) | 49b (46) | 48ac (18) | ||
| CWP | 49 | 55 (13) | 55 (25) | 46 (45) | 33 (22) | 42 (22) | 57 (20) | 42 (23) | 61 (47) | 60 (16) | ||
| Controls | 50 | 38 (10) | 88 (7) | 96 (5) | 80 (14) | 72 (21) | 69 (13) | 93 (12) | 86 (23) | 70 (9) | ||
| Walker et al. (1997) (USA)†(33) | ||||||||||||
| FM | 36 | 33.5 (22.7) | 8.8d (16.1) | 37.5e (16.1) | 54.4 (12.1) | 22.9d (16.7) | 36.7d (22.7) | 34.3d (38.9) | 56.2d (19.9) | 28.0 (6.6) | 38.6d (10.3) | |
| RA | 33 | 42.7 (27.1) | 32.0 (37.1) | 50.4 (21.1) | 61.5 (18.0) | 46.9 (23.4) | 70.7 (28.7) | 71.9 (40.4) | 75.4 (17.0) | 31.7 (9.8) | 52.8 (10.5) | |
| Reisine et al. (2004) (USA) (50) | SF-12 summary scores | |||||||||||
| FM | 287 | 47.0 (10.8) | 29.2a (8.5) | 42.1a (11.9) | ||||||||
| Controls | 286 | 47.0 (14.0) | 49.5 (9.2) | 49.8 (10.3) | ||||||||
SF-36, short-form health survey (36 items): SF-12, short-form health survey (12 items); PF, physical functioning; RP, role functioning difficulties caused by physical problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role functioning difficulties caused by emotional problems; MH, mental health; PCS, physical component summary; MCS, mental component summary. Higher scores indicate better health status. Pain conditions: FM, fibromyalgia; Dx, diagnosed; CWP, widespread pain; MPS, myofacial pain syndrome; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis.
All patients in all studies were women.
Statistical comparisons of FM groups with controls and other diagnostic groups:
FM group differed significantly from control group, p < 0.001
FM group differed significantly from control group, p < 0.01
FM group differed significantly from control group, p < 0.05
FM group differed significantly from diagnostic group, p < 0.001
FM group differed significantly from diagnostic group, p < 0.01
FM group differed significantly from diagnostic group, p < 0.05.